Dolled-Filhart, Marisa
Merck & Co., Inc., Rahway, NJ, USA (United States)
3 papers on CoChat
Most cited papers
- Verified
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 6,449
- Verified
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 6,198
- Verified
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Daud, A. I., Wolchok, J. D., Robert, C., Hwu, W.-J., Weber, J. S., Ribas, A., Hodi, F. S., Joshua, A. M., Kefford, R., Hersey, P., et al. (2016) · Journal of Clinical Oncology
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 665
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free